Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
172 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ischemic Stroke - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ischemic Stroke - Pipeline Review, H2 2014', provides an overview of the Ischemic Stroke's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ischemic Stroke - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ischemic Stroke and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ischemic Stroke pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ischemic Stroke - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ischemic Stroke pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Ischemic Stroke Overview 8 Therapeutics Development 9 Pipeline Products for Ischemic Stroke - Overview 9 Pipeline Products for Ischemic Stroke - Comparative Analysis 10 Ischemic Stroke - Therapeutics under Development by Companies 11 Ischemic Stroke - Therapeutics under Investigation by Universities/Institutes 14 Ischemic Stroke - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Ischemic Stroke - Products under Development by Companies 19 Ischemic Stroke - Products under Investigation by Universities/Institutes 22 Ischemic Stroke - Companies Involved in Therapeutics Development 23 Acorda Therapeutics, Inc. 23 advanceCor GmbH 24 AGY Therapeutics, Inc. 25 Angion Biomedica Corp. 26 Athersys, Inc. 27 BioTime, Inc. 28 Concert Pharmaceuticals, Inc. 29 Daiichi Sankyo Company, Limited 30 GlaxoSmithKline plc 31 Huons Co., Ltd. 32 Laboratoires Pierre Fabre SA 33 MediaPharma s.r.l. 34 Mesoblast Limited 35 Mitsubishi Tanabe Pharma Corporation 36 Neuralstem, Inc. 37 NeuroVive Pharmaceutical AB 38 Panacea Pharmaceuticals, Inc. 39 Pluristem Therapeutics Inc. 40 ReNeuron Group plc 41 Saneron CCEL Therapeutics, Inc. 42 Shin Poong Pharm.Co., Ltd. 43 The International Biotechnology Center (IBC) �Generium� 44 Torrent Pharmaceuticals Limited 45 Virogenomics, Inc. 46 Ischemic Stroke - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Target 48 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 AB-144 - Drug Profile 57 Allogenic Mesenchymal Precursor Cells for Parkinson's Disease and Stroke - Drug Profile 58 BB-3 - Drug Profile 59 C-10068 - Drug Profile 61 CEP-41750 - Drug Profile 62 CNB-001 - Drug Profile 64 dalfampridine ER - Drug Profile 66 Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 68 Fab-9O12 - Drug Profile 69 GNR-014 - Drug Profile 70 GSK-249320 - Drug Profile 72 HU-010 - Drug Profile 74 Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile 75 Ischemic Stroke Therapy - Drug Profile 78 levomilnacipran hydrochloride ER - Drug Profile 79 Lysimab - Drug Profile 81 Memantine Nitrone - Drug Profile 82 Monoclonal Antibody for Cardiovascular and Ischemic Stroke - Drug Profile 83 MPHE-001A - Drug Profile 84 MultiStem - Drug Profile 85 NSI-566 - Drug Profile 88 NVP-014 - Drug Profile 90 NVX-208 - Drug Profile 91 PAN-811 - Drug Profile 92 Pinocembrin - Drug Profile 94 Polyglactin 370 for Ischemic Stroke - Drug Profile 95 PR-15 - Drug Profile 96 prasugrel hydrochloride - Drug Profile 98 Protein for Ischemic Stroke - Drug Profile 100 Protein for Ischemic Stroke - Drug Profile 101 Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 102 ReN-001 - Drug Profile 103 RTL-551 - Drug Profile 104 Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile 105 Small Molecule to Block Sodium Channels for Ischemic Stroke - Drug Profile 106 Small Molecules for Brain Ischemia and Ischemic Stroke - Drug Profile 107 Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure - Drug Profile 108 Small Molecules to Block Sodium and hERG Channel for Ischemic Stroke - Drug Profile 109 Small Molecules to Inhibit AGY-207 for Ischemic Stroke - Drug Profile 110 Small Molecules to Inhibit AGY-221 for Ischemic Stroke - Drug Profile 111 Small Molecules to Inhibit CaMKII for Ischemic Stroke - Drug Profile 112 Small Molecules to Inhibit Cysteine Protease for Ischemic Stroke - Drug Profile 113 Small Molecules to Inhibit Kinase for Ischemic Stroke - Drug Profile 114 Small Molecules to Inhibit Protein Kinase for Ischemic Stroke - Drug Profile 115 SMTP-7 - Drug Profile 116 SP-8203 - Drug Profile 117 Stem Cell Therapy for Ischemic Stroke - Drug Profile 119 Stem Cell Therapy for Ischemic Stroke - Drug Profile 120 StromAb - Drug Profile 121 T-33 - Drug Profile 122 TPAi-14 - Drug Profile 123 TPAi-23 - Drug Profile 124 TRC-051384 - Drug Profile 125 TXA-127 - Drug Profile 126 TXA-302 - Drug Profile 128 Ischemic Stroke - Recent Pipeline Updates 130 Ischemic Stroke - Dormant Projects 157 Ischemic Stroke - Discontinued Products 158 Ischemic Stroke - Product Development Milestones 159 Featured News & Press Releases 159 Appendix 167 Methodology 167 Coverage 167 Secondary Research 167 Primary Research 167 Expert Panel Validation 167 Contact Us 168 Disclaimer 168
List of Tables Number of Products under Development for Ischemic Stroke, H2 2014 13 Number of Products under Development for Ischemic Stroke - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Products under Development by Companies, H2 2014 23 Products under Development by Companies, H2 2014 (Contd..1) 24 Products under Development by Companies, H2 2014 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2014 26 Ischemic Stroke - Pipeline by Acorda Therapeutics, Inc., H2 2014 27 Ischemic Stroke - Pipeline by advanceCor GmbH, H2 2014 28 Ischemic Stroke - Pipeline by AGY Therapeutics, Inc., H2 2014 29 Ischemic Stroke - Pipeline by Angion Biomedica Corp., H2 2014 30 Ischemic Stroke - Pipeline by Athersys, Inc., H2 2014 31 Ischemic Stroke - Pipeline by BioTime, Inc., H2 2014 32 Ischemic Stroke - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 33 Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 34 Ischemic Stroke - Pipeline by GlaxoSmithKline plc, H2 2014 35 Ischemic Stroke - Pipeline by Huons Co., Ltd., H2 2014 36 Ischemic Stroke - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 37 Ischemic Stroke - Pipeline by MediaPharma s.r.l., H2 2014 38 Ischemic Stroke - Pipeline by Mesoblast Limited, H2 2014 39 Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 40 Ischemic Stroke - Pipeline by Neuralstem, Inc., H2 2014 41 Ischemic Stroke - Pipeline by NeuroVive Pharmaceutical AB, H2 2014 42 Ischemic Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 43 Ischemic Stroke - Pipeline by Pluristem Therapeutics Inc., H2 2014 44 Ischemic Stroke - Pipeline by ReNeuron Group plc, H2 2014 45 Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 46 Ischemic Stroke - Pipeline by Shin Poong Pharm.Co., Ltd., H2 2014 47 Ischemic Stroke - Pipeline by The International Biotechnology Center (IBC) "Generium", H2 2014 48 Ischemic Stroke - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 49 Ischemic Stroke - Pipeline by Virogenomics, Inc., H2 2014 50 Assessment by Monotherapy Products, H2 2014 51 Number of Products by Stage and Target, H2 2014 53 Number of Products by Stage and Mechanism of Action, H2 2014 56 Number of Products by Stage and Route of Administration, H2 2014 58 Number of Products by Stage and Molecule Type, H2 2014 60 Ischemic Stroke Therapeutics - Recent Pipeline Updates, H2 2014 134 Ischemic Stroke - Dormant Projects, H2 2014 161 Ischemic Stroke - Discontinued Products, H2 2014 162
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
